In a nutshell The study evaluated outcomes of lapatinib (Tykerb), trastuzumab (Herceptin), and aromatase inhibitor (AI) in postmenopausal women with human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) metastatic breast cancer (MBC). The authors found that the combination was safe and effective in such...Read More
Confined or spread disease-Spread to regional lymph nodes Posts on Medivizor
In a nutshell This study looked at the effects after stopping immune therapy in patients with advanced melanoma. They found that responses to treatment lasted long after treatment was stopped. Some background Stage 3 or 4 melanoma refers to a tumor that has spread to lymph nodes or distant organs. At this advanced stage, the cancer...Read More
An examination of pertuzumab and trastuzumab as breast cancer treatment before surgery in a real-life setting
In a nutshell This study examined the effectiveness and safety of the drug combination pertuzumab (Perjeta) and trastuzumab (Herceptin) as a treatment for breast cancer (BC) with positive HER2 (human epidermal growth factor receptor 2) before surgery to remove the tumor in a real-world setting. The data showed that this...Read More
Can a combination of dabrafenib and trametinib improve relapse-free survival after removal of stage 3 melanoma?
In a nutshell This study investigated the long-term effectiveness and risks of the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with stage 3 melanoma after tumor removal. It showed that the combination of the two drugs can increase survival without return or spreading of cancer. Some...Read More
In a nutshell This trial is aiming to examine the effectiveness of an experimental drug, AMXI-5001, in patients with advanced breast cancer. The main outcomes that are to be measured in this trial are side effects and the response to treatment. This trial is going to be carried out in California, Tennessee, and Florida, the United States. The...Read More
The effects of cholesterol-lowering drugs on breast cancer relapse in postmenopausal women under aromatase inhibitor treatment
In a nutshell The study evaluated the link between statin (cholesterol-lowering drugs) use and risks of breast cancer (BC) relapse under adjuvant aromatase inhibitors (AI) therapy in women after their menopause. The main finding was that statin use was related with lower risks of BC relapse in such patients. Some background Women with...Read More
Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?
In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...Read More
How common are allergic reactions to different biological therapies in patients with advanced melanoma?
In a nutshell This study compared the frequency of allergic reactions to different doses of three biological therapies in patients with advanced melanoma. The authors found that different doses of the three drugs reduced the number of allergic reactions. Some background Biological therapy has significantly improved treatment results for patients...Read More
In a nutshell This study looked at fertility preservation (FP) in patients with breast cancer. It found that many patients choose FP before chemotherapy and that most patients have a return of ovulation following treatment. Some background 12% of patients newly diagnosed with breast cancer are under 40 years of age. Preserving fertility is a concern...Read More
Does it matter how much healthy tissue is removed during surgery for patients with breast cancer who received chemotherapy first?
In a nutshell This study examined if there was a difference in patients with breast cancer first treated with chemotherapy that had a wide or narrow margin of healthy tissue removed during surgery. The results showed that the outcomes were similar regardless of how much healthy tissue was removed. Some background Traditionally, mastectomy (the...Read More
Long-term outcomes of pertuzumab added to trastuzumab and docetaxel treatment for patients with advanced HER2-positive breast cancer
In a nutshell This study looked at whether pertuzumab (Perjeta) benefits patients with metastatic HER2-positive breast cancer when added to trastuzumab (Herceptin) and docetaxel (Taxotere) treatment. They found that adding pertuzumab improved long-term patient outcomes. Some background Breast cancer can now be tested for some of the signals involved...Read More
In a nutshell This study aimed to investigate the effectiveness and safety of atezolizumab plus nab-paclitaxel in unresectable, locally advanced or metastatic triple-negative breast cancer. This study concluded that this combination had a benefit in patients with PD-L1 immune cell positive...Read More